A practical reference on subcutaneous dosing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-08 and is reviewed periodically as new material appears.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
=== 2010-2013 === A book A Little War That Shook the World by Ronald Asmus was published in January 2010. One staff worker for Dick Cheney is quoted as expressing concern that American president George W. Bush had probably given Putin a "green light" to start hostilities against Georgia during the April 2008 meeting in Sochi. The book reported that French president Sarkozy said that he was ready to confront Russia on Georgia's NATO membership, but not German Chancellor Merkel. Germany's refusal to submit to the US proposal was a first time the US interests were neglected in the NATO and Putin used NATO's hesitation as an opportunity to wage the war against its neighbor. Asmus stated: "Many in the West tried to step back and pretend that the Russo-Georgian war was a local conflict they were not a party to." In October 2011, Dmitry Rogozin said in an interview with Echo of Moscow that Russia achieved that Ukraine and Georgia did not become NATO members and Russia gained respect. In 2011, Condoleezza Rice, former Secretary of State, published her memoirs where she wrote that she had told Saakashvili before the war not to respond to Russia because nobody would help him. She told The Weekly Standard that "But in no way were the Georgians at fault..." She said: "They were doing all kinds of things to try to provoke the Georgians. The shelling of Georgian cities by the South Ossetians, Russian allies, is clearly what started the war." Rice also talked about Russian hatred for Georgians.
The skin is the largest organ of the human body that restricts the movement of drug to the systemic circulation. The topical drug delivery system is a system where the drug reaches the systemic circulation through the protective skin layer. The main disadvantage of this route is the low diffusion rate of the drugs across the layer of skin which is the stratum corneum. To overcome this problem to a certain extent, ethosomes are used to enhance transdermal drug delivery systems.
Although the anti-American films were notably popular with audiences, the Ministry did not feel the message had reached the general public, perhaps due to the fact that the majority of moviegoers seeing the films produced were, perhaps, the Soviets most likely to admire American culture. After Stalin's death, a Main Administration of Cinema Affairs replaced the Ministry, allowing the filmmakers more freedom due to the lack of direct government control. Many of the films released throughout the late 1950s and 1960s focused on spreading a positive image of Soviet life, intent to prove that Soviet life was indeed better than American life. Russian science fiction emerged from a prolonged period of censorship in 1957, opened up by de-Stalinization and real Soviet achievements in the space race, typified by Ivan Efremov's galactic epic, Andromeda (1957). Official Communist science fiction transposed the laws of historical materialism to the future, scorning Western nihilistic writings and predicting a peaceful transition to universal communism. Scientocratic visions of the future nevertheless implicitly critiqued the bureaucratically developed socialism of the present. Dissident science fiction writers emerged, such as the Strugatski brothers, Boris and Arkadi, with their "social fantasies," problematizing the role of intervention in the historical process, or Stanislaw Lem's tongue-in-cheek exposures of man's cognitive limitations.
The 51st G7 summit, the 57th annual meeting of the G7, was held from 16 to 17 June 2025 in Kananaskis, Alberta, Canada. This was the 2nd G7 summit to be held in Kananaskis since the 28th G8 summit in 2002, and the seventh summit held in Canada.
=== Contact inhibition of locomotion === Contact inhibition of locomotion (CIL) is a process in which the cell changes its direction of movement after colliding into another cell. Those cells could be of the same cell type or different types. The contacts (cell-junctions) are created by transmembrane glycoproteins named cadherins (E-cadherin, N-cadherin or cadherin 11) and other proteins. After cell-cell contact, the protrusions of cells in the contact direction are inhibited. In the CIL process, cells migrate away from each other by repolarizing in the new direction, so that new protrusions are formed in the front while contractions pull the back from contact.
Sources: en.wikipedia.org
During the COVID-19 pandemic, women's food insecurity rose faster than men's, and job losses in both primary agricultural production and off-farm segments of the agrifood systems were much more pronounced for women than for men. Women were called on to draw down their more limited assets and savings more quickly than were men.
=== Virus adaptation to grow in cell cultures === SeV strain variants adapted for growth in different cells have different properties. One study shows that the SeV variant adapted for growth in LLC-MK2 cells and the SeV variant adapted for growth in embryonated eggs differ by two amino acids in the HN protein. This difference results in different neuraminidase conformations around the receptor binding site and variations in neuraminidase activity between the two viral variants. Another research study shows that SeV variants, adapted to grow in cell culture 4647 (African green monkey kidney cells) and in HEK 293 (human embryonic kidney cells) instead of embryonated chicken eggs, also acquire mutations in HN gene and both SeV variants lost their oncolytic activity.
== Medical uses == Hydrocodone is used to treat moderate to severe pain. In liquid formulations, it is used to treat coughing. In one study comparing the potency of hydrocodone to that of oxycodone, it was found that it took 50% more hydrocodone to achieve the same degree of miosis (pupillary contraction). The investigators interpreted this to mean that oxycodone is about 50% more potent than hydrocodone. However, in a study of emergency department patients with fractures, it was found that an equal amount of either drug provided about the same degree of pain relief, indicating that there is little practical difference between them when used for that purpose. Some references state that the analgesic action of hydrocodone begins in 20–30 minutes and lasts about 4–8 hours. The manufacturer's information says onset of action is about 10–30 minutes and duration is about 4–6 hours. Recommended dosing interval is 4–6 hours. Hydrocodone reaches peak serum levels after 1.3 hours.
If a designer is interested only in the best sequence, the protein design algorithm only requires the lowest-energy conformation of the lowest-energy sequence. In these cases, the amino acid identity of each rotamer can be ignored and all rotamers belonging to different amino acids can be treated the same. Let ri be a rotamer at residue position i in the protein chain, and E(ri) the potential energy between the internal atoms of the rotamer. Let E(ri, rj) be the potential energy between ri and rotamer rj at residue position j. Then, we define the optimization problem as one of finding the conformation of minimum energy (ET):
=== Pregnancy === Oxazepam, when taken during the third trimester, causes a definite risk to the neonate, including a severe benzodiazepine withdrawal syndrome including hypotonia, reluctance to suck, apnoeic spells, cyanosis, and impaired metabolic responses to cold stress. Floppy infant syndrome and sedation in the newborn may also occur. Symptoms of floppy infant syndrome and the neonatal benzodiazepine withdrawal syndrome have been reported to persist from hours to months after birth.
Sources: en.wikipedia.org
=== Health === On May 18, 2025, Biden's office announced that he had been diagnosed with aggressive prostate cancer with bone metastasis during a routine physical examination. On May 30, Biden confirmed that he had begun treatment. On September 4, Biden's spokesperson confirmed that he had recently undergone Mohs surgery to remove skin cancer lesions from his forehead. The procedure followed a 2023 removal of a basal-cell carcinoma from his chest. On October 11, Biden's spokesperson confirmed that he was undergoing radiation and hormone therapies for his prostate cancer. On October 20, Biden completed a course of radiation therapy at Penn Medicine Radiation Oncology at the University of Pennsylvania. In August 2026, Hunter Biden said the cancer had "spread, metastasized into his bones and further" and was "very painful and it's very debilitating in many respects". In September 2026, Biden announced that the radiation treatment he received for prostate cancer last fall "worked as intended" and that doctors helped in disease control.
=== Third-generation === Third generation antipsychotics are recognized as demonstrating D2 receptor partial agonism as opposed to the D2 and 5HT-2A receptor antagonism of second-generation (atypical) antipsychotics and D2 antagonism of first-generation (typical) antipsychotics.
Thiotepa, as well as its more reactive metabolite, tepa, work as an alkylating agent via its aziridine ring. Due to the basic nature of aziridine and the physiological pH, aziridine is protonated to form the aziridinium ion, resulting in an electrophilic moiety that is highly susceptible to nucleophiles. DNA reacts through the nucleophilic N-7 position of guanine onto the electrophilic aziridine ring, rendering alkylated nucleobases. Thiotepa contains three reactive aziridine rings, allowing a single molecule to alkylate multiple nucleobases. Hence, it is a polyfunctional alkylating agent. This property also gives rise to its ability to cross-link DNA strands. Apart from its mechanism of action, it is suggested that thiotepa can function as a prodrug. Due to its moderate lipophilicity, it first penetrates the cell membrane, followed by hydrolysis to release the more hydrophilic aziridine ring. The aziridine ring can once again alkylate the DNA. The highly reactive metabolite tepa can be considered as an active metabolite and alkylates DNA similar to its parent drug. Ultimately, the alkylation of DNA leads to cell damage and can lead to cell death. Cross-linking blocks the separation of DNA strands, inhibiting replication and the proliferation of cells.
The Miami Herald reported on 2 October 2025 that sources said the US effort had "effectively shut down" the busy "Caribbean route" for estimated 2024 annual shipments of between 350 and 500 tons of cocaine coming from Venezuela. According to the Miami Herald, the campaign's "goal is financial: cutting off the drug revenue that sustains loyalty among Venezuela's senior military and police commanders, many of whom are accused of profiting directly from narcotrafficking." Trafficking through older air and land routes from Colombia are more costly than maritime shipments, and sources said that Venezuelan "cash flow from trafficking is under direct threat, and that puts the cohesion of the military elite at risk", with "authorities [turning] to heavier taxation and extortion of businesses to keep the state's security apparatus afloat." According to The Economist, "Few ... think drugs are the sole or even the main focus" of the operation, noting that fentanyl, the drug that causes the most deaths in the US, is almost entirely "synthesized in Mexico and trafficked north over land" and that "the hardware"—e.g. destroyers—"doesn't match the task" of drug policing.
=== Congenital adrenal hyperplasia === In congenital adrenal hyperplasia, the adrenal cortex lacks appropriate corticosteroid synthesis, leading to excess adrenal androgens and affects female fetuses. There is an external masculinization of the genitalia in the female fetuses. Mothers of at risk fetuses are given dexamethasone at 6 weeks gestation to suppress pituitary gland release of androgens. If analysis of cffDNA obtained from a sample of maternal plasma lacks genetic markers found only on the Y chromosome, it is suggestive of a female fetus. However, it might also indicate a failure of the analysis itself (a false negative result). Paternal genetic polymorphisms and sex-independent markers may be used to detect cffDNA. A high degree of heterozygosity of these markers must be present for this application.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.